- $13.35m
- $12.16m
- $22.10m
- 62
- 54
- 15
- 40
Annual income statement for Psychemedics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 37.7 | 21.4 | 24.9 | 25.2 | 22.1 |
| Cost of Revenue | |||||
| Gross Profit | 16.4 | 4.89 | 10.3 | 9.29 | 8.41 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 34.7 | 27.4 | 25.7 | 26.3 | 25.5 |
| Operating Profit | 3 | -6.07 | -0.76 | -1.08 | -3.43 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.06 | -6.21 | -0.821 | -1.04 | -3.44 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.54 | -3.86 | -0.665 | -1.08 | -4.15 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.54 | -3.86 | -0.665 | -1.08 | -4.15 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.54 | -3.86 | -0.665 | -1.08 | -4.15 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.279 | -0.699 | -0.006 | -0.193 | -0.666 |
| Dividends per Share |